ICMAD: Small Business Looks To Pull Off Preemption Balancing Act
This article was originally published in The Rose Sheet
National uniformity in cosmetics regulation remains a top legislative priority for the Independent Cosmetic Manufacturers and Distributors. At the same time, the small business trade association acknowledges that compromise will likely be needed to balance state rights with the streamlined certainty that a strong national standard would provide for industry.
You may also be interested in...
WEN is “new” spelled backwards, but the safety scrutiny facing the hair-care brand is anything but. FDA continues to investigate related adverse-event reports, but 2017 could be the year that Guthy-Renker and Chaz Dean dispense with the lion’s share of consumer complaints and associated payouts.
EWG maintains that “the result of the election has no effect whatsoever on the need for cosmetics reform,” but it remains to be seen how legislative proposals for increased oversight would be received by the president-elect, who has outlined plans for dramatically cutting perceived overregulation. Meanwhile, new leadership is likely to be appointed at FDA, and hopes dwindle regarding the Trans-Pacific Partnership.
The Cosmetic Modernization Amendments of 2015 is touted by small business as a more appropriately sized update to the regulatory framework than the front-running PCPSA. However, some provisions seen as vital are absent from the bill, while its call for FDA to accept CIR safety decisions could be deemed unconstitutional, an FDA official suggests in a letter to Senate HELP Committee Chair Lamar Alexander.